Screener
Bausch + Lomb BLCO Pharmaceuticals — Selling, general and administrative (Note 4)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001860742-26-000088
| (in millions) | Vision Care / Three Months Ended June 30, 2026 | Vision Care / Three Months Ended June 30, 2025 | Pharmaceuticals / Three Months Ended June 30, 2026 | Pharmaceuticals / Three Months Ended June 30, 2025 | Surgical / Three Months Ended June 30, 2026 | Surgical / Three Months Ended June 30, 2025 | Total / Three Months Ended June 30, 2026 | Total / Three Months Ended June 30, 2025 |
|---|---|---|---|---|---|---|---|---|
| Expenses | ||||||||
| Cost of goods sold (excluding amortization and impairments of intangible assets) | 291 | 290 | 89 | 104 | 147 | 129 | ||
| Cost of other revenues | — | — | — | 2 | — | — | ||
| Selling, general and administrative | 247 | 243 | 149 | 154 | 80 | 73 | ||
| Research and development | 17 | 11 | 27 | 12 | 12 | 12 | ||
| Segment Profit | $229 | $209 | $89 | $37 | $17 | $2 | 335 | 248 |
| Corporate | (170) | (170) | ||||||
| Amortization of intangible assets | (57) | (67) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4)?
- Bausch + Lomb (BLCO) reported pharmaceuticals — selling, general and administrative (note 4) of $149M in Q2 2026.
- How has Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4) changed year-over-year?
- Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4) decreased by 3.2% year-over-year, from $154M to $149M.
- What is the long-term trend for Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4)?
- Over 3 years (2022 to 2025), Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4) has grown at a 35.5% compound annual growth rate (CAGR), from $230M to $572M.
- What does pharmaceuticals — selling, general and administrative (note 4) mean?
- Includes the indirect costs associated with operating the pharmaceutical segment, such as marketing, sales force compensation, and administrative overhead. Monitoring this metric helps assess the operational efficiency and the cost-to-serve ratio of the segment's commercial activities.
Ask your AI about Bausch + Lomb's pharmaceuticals — selling, general and administrative (note 4).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude